The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

afnm.com

Founded Year

2000

Stage

Debt | Alive

Total Raised

$44.9M

Last Raised

$11.9M | 9 yrs ago

About Affinium Pharmaceuticals

Affinium Pharmaceuticals is a specialty pharmaceutical company developing a class of antibiotics that target the bacterial fatty acid synthesis (FASII) pathway. AFN-1252, the company's lead clinical compound, is a highly-potent, small molecule antibiotic for both oral and IV treatment of staphylococcal infections, including MRSA and all other drug-resistant strains.

Affinium Pharmaceuticals Headquarter Location

200 Front Street West Suite 3004

Toronto, Ontario, M5V 3K2,

Canada

416-645-6613

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Affinium Pharmaceuticals

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Affinium Pharmaceuticals is included in 1 Expert Collection, including Biopharma Tech.

B

Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Affinium Pharmaceuticals Patents

Affinium Pharmaceuticals has filed 16 patents.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

11/8/2013

1/9/2018

Metabolism, EC 2.3.1, Antibiotics, Protein domains, EC 1.1.1

Grant

Application Date

11/8/2013

Grant Date

1/9/2018

Title

Related Topics

Metabolism, EC 2.3.1, Antibiotics, Protein domains, EC 1.1.1

Status

Grant

Latest Affinium Pharmaceuticals News

Ontario investment in biotech pays off

Apr 8, 2015

April 07 Print This Article Share it With Friends The Ontario Capital Growth Corporation (OCGC) has announced that it has received more than three times its investment in Affinium Pharmaceuticals after the company’s acquisition by Debiopharm International. The acquisition to this Swiss-based global biopharmaceutical company has given OCGC $19 million. OCGC made its initial investment into Toronto-based Affinium in 2011, alongside other investors including Canadian Genesys Capital Management. “As Canada’s most active early stage life sciences venture investor, one of the biggest challenges we face is getting capital together to make investments like these,” said Damian Lamb, Managing Director at Genesys. “As the lead investor, Genesys worked with OCGC and our international partners to provide the financial resources necessary for Affinium’s success.” Senior Affinium management have joined with partners including Debiopharm to launch Nobelex Biotech Inc, which will focus on the development of anti-infection drugs. Based in the Toronto MaRS Discovery District, the company has already begun research and is quickly expanding its employee base.

Affinium Pharmaceuticals Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Affinium Pharmaceuticals Rank

  • When was Affinium Pharmaceuticals founded?

    Affinium Pharmaceuticals was founded in 2000.

  • Where is Affinium Pharmaceuticals's headquarters?

    Affinium Pharmaceuticals's headquarters is located at 200 Front Street West, Toronto.

  • What is Affinium Pharmaceuticals's latest funding round?

    Affinium Pharmaceuticals's latest funding round is Debt.

  • How much did Affinium Pharmaceuticals raise?

    Affinium Pharmaceuticals raised a total of $44.9M.

  • Who are the investors of Affinium Pharmaceuticals?

    Investors of Affinium Pharmaceuticals include SV Health Investors, Genesys Capital, Forward Ventures, Oxford Bioscience Partners, Ontario Emerging Technologies Fund and 13 more.

  • Who are Affinium Pharmaceuticals's competitors?

    Competitors of Affinium Pharmaceuticals include Tetraphase Pharmaceuticals, Viamet Pharmaceuticals, Akebia Therapeutics, Altor BioScience, CoLucid Pharmaceuticals and 12 more.

You May Also Like

I
Inimex Pharmaceuticals

Inimex Pharmaceuticals, Inc. is focused on the development and commercialization of Innate Defense Regulators (IDRs), first in class drugs that selectively trigger the body's innate defenses without causing inflammation. IDR products have major market potential for infectious disease, cancer, and inflammatory disease. These products will reduce morbidity and mortality in the rapidly growing population of immune suppressed and elderly patients who are "at-risk" for these disorders. IDR products will also benefit healthcare payors by reducing costs associated with hospitalization. Inimex' lead IDR product IMX942 targets a broad spectrum of life-threatening hospital infections, many of which are caused by antibiotic-resistant bacteria such as methicillin-resistant Staphylococcus aureus (MRSA) or vancomycin-resistant Enterococcus (VRE). IMX942 is active against both normal and drug-resistant bacteria and its ability to stimulate host innate immune defenses is not susceptible to bacterial antibiotic resistance mechanisms. The first clinical indication for IMX942 will be the prevention of infections associated with cancer chemotherapy-induced immune suppression. nnAdditional IDR product candidates will be developed for distinct disease areas, with an emphasis on inflammatory disease and demonstration of the potential for orally available IDR dosage forms.

O
Oculus Innovative Sciences

Oculus Innovative Sciences develops, manufactures and markets a family of products based upon the Microcyn® Technology platform, which is intended to help prevent and treat infections in chronic and acute wounds. The Microcyn Technology platform features a biocompatible, shelf-stable solution containing active oxychlorine compounds that is currently commercialized in the United States, Europe, India, China and Mexico for the treatment of infected wounds. The solutions derived from this platform have demonstrated, in a variety of research and investigational studies, the ability to treat a wide range of pathogens, including antibiotic-resistant strains of bacteria (including MRSA and VRE), viruses, fungi and spores. The company's headquarters are in Petaluma, California, with operations in Europe and Latin America.

A
Ancora Pharmaceuticals

Ancora Pharmaceuticals aims to enable synthetic carbohydrate-based product discovery and development utilizing its carbohydrate synthesis capability, which is based on technology originally developed at the Massachusetts Institute of Technology (M.I.T.). The company is applying its synthesis technology both to internal drug development programs and strategic collaborations within the pharmaceutical and biotechnology sector.

L
Locus Pharmaceuticals

Locus Pharmaceuticals is a privately held pharmaceutical company focused on developing small molecule therapeutic drugs to address unmet medical needs. The company's core technology is a fragment-based, computational approach, which Locus has combinated with highly integrated medicinal chemistry, crystallography and biology capabilities to create a unique drug design and development platform.

U
Ulysses Pharmaceuticals

Ulysses Pharmaceuticals is dedicated to the discovery and development of safe antimicrobial agents for the treatment of severe and recurrent infections occurring in humans. The Company intends to become an industry leader in the antiinfective field through the development of new antibiotics including some acting as Trojan Horses that take advantage of essential microbial transport systems to specifically enter targeted pathogens. Ulysses concentrates on the development of advanced hit and lead compounds with promising features and characteristics that are indicative of potent antibacterial agents with potential for strong market penetration.

B
Bexion Pharmaceuticals

Bexion Pharmaceuticals is a company focused on the development of cures for cancer. Specifically, the company is interested in first entering the clinic with a glioma cancer indication, possibly simultaneously with a leukemia or pancreatic cancer indication.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.